Drug Profile
Indinavir - Merck
Alternative Names: Crixivan; Indinavir sulfate; L 735524; MK 639Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme
- Class Antiretrovirals; Pyridines
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 24 Jul 2005 Merck Sharp & Dohme LLC in collaboration with Agouron Pharmaceuticals completes a phase II trial for HIV infections in USA (NCT00002235)
- 24 Jun 2005 Merck Sharp & Dohme LLC in collaboration with NIH completes a phase III trial for HIV infections in USA (NCT00002406)
- 23 Jun 2005 Merck Sharp & Dohme completes a clinical trial for HIV Infections in June 2005 (NCT00002430)